104
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Time to colonoscopy, cancer probability, and precursor lesions in the Danish colorectal cancer screening program

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 659-667 | Published online: 30 Jul 2019

References

  • Iversen LH, Green A, Ingeholm P, Osterlind K, Gogenur I. Improved survival of colorectal cancer in Denmark during 2001-2012 – the efforts of several national initiatives. Acta Oncol. 2016;55(Suppl 2):10–23. doi:10.3109/0284186X.2015.113133126859340
  • Fitzpatrick-Lewis D, Ali MU, Warren R, Kenny M, Sherifali D, Raina P. Screening for colorectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer. 2016;15(4):298–313. doi:10.1016/j.clcc.2016.03.00327133893
  • Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet (London, England). 1996;348(9040):1467–1471. doi:10.1016/S0140-6736(96)03430-7
  • Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106–1114. doi:10.1056/NEJMoa130072024047060
  • Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2012;61(7):1036–1040. doi:10.1136/gutjnl-2011-30077422052062
  • von Karsa L, Patnick J, Segnan N, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(1):51. doi:10.1055/s-0032-132599723212726
  • Danish Colorectal Cancer Screening Database. Dansk Tarmkræftscreeningsdatabase Årsrapport 2016 [Annual Report of the Danish Colorectal Cancer Screening Database 2016]. København: Dansk tarmkræftscreeningsdatabase (DTS); 12 2017.
  • Toes-Zoutendijk E, van Leerdam ME, Dekker E, et al. Real-time monitoring of results during first year of dutch colorectal cancer screening program and optimization by altering fecal immunochemical test cut-off levels. Gastroenterology. 2017;152(4):767–775.e762. doi:10.1053/j.gastro.2016.11.02227890769
  • Brenner H, Werner S. Selecting a cut-off for colorectal cancer screening with a fecal immunochemical test. Clin Transl Gastroenterol. 2017;8(8):e111. doi:10.1038/ctg.2017.3728771240
  • Stracci F, Zorzi M, Grazzini G. Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health. 2014;2:210. doi:10.3389/fpubh.2014.0021025386553
  • Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–1297. doi:10.1056/NEJMoa131119424645800
  • Steele RJ, Kostourou I, McClements P, et al. Effect of gender, age and deprivation on key performance indicators in a FOBT-based colorectal screening programme. J Med Screen. 2010;17(2):68–74. doi:10.1258/jms.2010.00912020660434
  • Morris S, Baio G, Kendall E, et al. Socioeconomic variation in uptake of colonoscopy following a positive faecal occult blood test result: a retrospective analysis of the NHS Bowel Cancer Screening Programme. Br J Cancer. 2012;107(5):765–771. doi:10.1038/bjc.2012.30322864455
  • Ferrat E, Le Breton J, Veerabudun K, et al. Colorectal cancer screening: factors associated with colonoscopy after a positive faecal occult blood test. Br J Cancer. 2013;109(6):1437–1444. doi:10.1038/bjc.2013.47623989948
  • Deding U, Henig AS, Salling A, Torp-Pedersen C, Boggild H. Sociodemographic predictors of participation in colorectal cancer screening. Int J Colorectal Dis. 2017;32(8):1117–1124. doi:10.1007/s00384-017-2832-628501944
  • Deding U, Henig AS, Hindersson P, Torp-Pedersen C, Bøggild H. Determinants of non-participation in colon examination following positive stool sample in colorectal cancer screening. Eur J Public Health. 2019. doi:10.1093/eurpub/ckz072
  • Corley DA, Jensen CD, Quinn VP, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA. 2017;317(16):1631–1641. doi:10.1001/jama.2017.363428444278
  • Gellad ZF, Almirall D, Provenzale D, Fisher DA. Time from positive screening fecal occult blood test to colonoscopy and risk of neoplasia. Dig Dis Sci. 2009;54(11):2497–2502. doi:10.1007/s10620-008-0653-819093199
  • Peterson K, Carson S, Humphrey L, Helfand M. Patients with Positive Screening Fecal Occult Blood Tests: Evidence Brief on the Relationship between Time Delay to Colonoscopy and Colorectal Cancer Outcomes. Clin Gastroenterol Hepatol. 2016;14(10):1445–1451.e8.
  • Shah HA, Paszat LF, Saskin R, Stukel TA, Rabeneck L. Factors associated with incomplete colonoscopy: a population-based study. Gastroenterology. 2007;132(7):2297–2303. doi:10.1053/j.gastro.2007.03.03217570204
  • Koido S, Ohkusa T, Nakae K, et al. Factors associated with incomplete colonoscopy at a Japanese academic hospital. World J Gastroenterol. 2014;20(22):6961–6967. doi:10.3748/wjg.v20.i22.696124944489
  • Palmer CK, Thomas MC, von Wagner C, Raine R. Reasons for non-uptake and subsequent participation in the NHS Bowel Cancer Screening Programme: a qualitative study. Br J Cancer. 2014;110(7):1705–1711. doi:10.1038/bjc.2014.12524619071
  • Jones RM, Devers KJ, Kuzel AJ, Woolf SH. Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. Am J Prev Med. 2010;38(5):508–516. doi:10.1016/j.amepre.2010.01.02120409499